Table 11.
Resistance rates in China, U.S. and Kuwait, hospital surveillance data for 2001
| From Tables 1,2,3,8 and 9; Unit: % | |||||
| Bacterium(a) | Antibiotic(s) | Pair | China | U.S. | Kuwait |
| SAU | Methicillin | A | 37 | 38 | 9 |
| SPN | Erythromycin | B | 73 | 19 | 23 |
| Cefotaxime | C | 0 | 16 | 4 | |
| Enterococcus spp | Vancomycin | D | 4 | 10 | 0 |
| ECO | Ceftazidime | E | 9 | 1* | 5 |
| Cefotaxime | F | 18 | 1* | 1 | |
| Ceftriaxone | G | 21 | 1* | 1 | |
| Ciprofloxacin/Ofloxacin | H | 56 | 3 | 26 | |
| PAE | Ceftazidime | I | 17 | 9 | 27 |
| Ciprofloxacin/Ofloxacin | J | 27 | 28 | 31 | |
| KPN | Ceftazidime | K | 9 | 4* | 14 |
| Cefotaxime | L | 17 | 4* | 13 | |
| Ceftriaxone | M | 20 | 4* | 13 | |
| Ciprofloxacin | N | 18 | 12**[27] | 18 | |
| Salmonella spp | Amoxicillin-clavulanate | O | 10 | 4 | 7 |
| Ceftriaxone | P | 5 | 1 | 0 | |
| Ciprofloxacin | Q | 0 | 0.4 | 10 | |
| TMP/SMX*** | R | 0 | 3 | 0 | |
| Gentamicin | S | 10 | 2 | 0 | |
| Shigella spp | Amoxicillin-clavulanate | T | 35 | 2 | 20 |
| Ceftriaxone | U | 6 | 0 | 0 | |
| Ciprofloxacin | V | 6 | 0 | 0 | |
| TMP/SMX | W | 0 | 53 | 0 | |
| Gentamicin | X | 18 | 0.2 | 0 | |
| Average | 17 | 7 | 9 | ||
* The original U.S. NNIS reported resistance rates to either one of the Cef3 drugs, i.e. ceftazidime, cefotaxime or ceftriaxone. We assume the same rates for each drug.
** Based on surveillance of ICU patients
*** TMP/SMX = Trimethoprim/Sulfamethoxazole